CanadaTZIELD (teplizumab for injection), 2 mg per 2 mL (1 mg/mL) for intravenous infusion, sold nationally in Canada, is affected. Serious and life-threatening cases of viral reactivation, including Epstein–Barr virus (EBV) and cytomegalovirus (CMV), have been reported with TZIELD; see Key Messages below for what to do.
How to identify it
TZIELD, teplizumab for injection, 2 mg per 2 mL (1 mg/mL) for intravenous infusion
The hazard
Serious and life-threatening cases of viral reactivation, including Epstein–Barr virus (EBV) and cytomegalovirus (CMV), have been reported with TZIELD.
What to do
See Key Messages below
Where it was sold
National
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)